ClinicalTrials.gg
CompletedNCT00846027Updated Jul 23, 2014Results posted

A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer

A Phase 2 interventional study of Bevacizumab and Paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 23 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-23.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
48th of 130
90 · median 58
Started
2009
with 9 others
Phase 2
89 of 131
6 open now
Registered
79th of 131
by date
Lead sponsor
14 of 131
Hoffmann-La Roche

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 48th largest by enrollment of the 130 interventional ones that give a count, is one of 10 that started in 2009, is one of 89 in phase 2, and was the 79th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This single-arm study assessed the efficacy and safety of first-line treatment with Avastin (bevacizumab) in combination with taxane-based chemotherapy (paclitaxel and gemcitabine) in patients with HER-2 negative breast cancer. Patients received Avastin 10 mg/kg iv, paclitaxel 150 mg/m\^2 iv, and gemcitabine 200 mg/m\^2 iv on Day 1 and Day 15 of each 4-week treatment cycle until disease progression, death, or withdrawal of consent.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients, ≥ 18 years of age.
  • Breast cancer, with measurable, locally recurrent or lesions, or patients with bone metastasis only.
  • negative disease.
  • Candidates for chemotherapy.
  • (ECOG) performance status ≤ 2.

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for or locally advanced breast cancer.
  • Previous radiotherapy for treatment of metastatic breast cancer.
  • Any prior treatment with anthracyclines completed \< 6 months prior to enrollment.
  • Chronic daily treatment with (≥ 10 mg/day), aspirin (> 325 mg/day) or clopidogrel (> 75mg/day).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Bevacizumab + paclitaxel + gemcitabine

    Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m\^2 IV, and gemcitabine 2000 mg/m\^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.

    Drug: Bevacizumab · Drug: Paclitaxel · Drug: Gemcitabine

Interventions

  • Bevacizumab was supplied as a sterile liquid in glass vials.

    Also known as: Avastin

  • Paclitaxel was supplied as a sterile liquid in glass vials.

    Also known as: Taxol

  • Gemcitabine was supplied as a sterile liquid in glass vials.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.

    Time frame: Baseline to the end of the study (up to 2 years 10 months)

Secondary outcomes

  1. Percentage of Participants With an Objective Response

    An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.

    Time frame: Baseline to the end of the study (up to 2 years 10 months)

  2. Duration of the Objective Response

    Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.

    Time frame: Baseline to the end of the study (up to 2 years 10 months)

  3. Overall Survival

    Overall survival is defined as the time from the first dose of study medication until death.

    Time frame: Baseline to the end of the study (up to 2 years 10 months)

07

Results

Posted Jun 26, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Paclitaxel + Gemcitabine
Started90
Received treatment83
Completed0
Not completed90
Withdrew: Death3
Withdrew: Disease progression30
Withdrew: Toxicity12
Withdrew: Patient decision7
Withdrew: Investigator discretion29
Withdrew: Protocol violation2
Withdrew: Subject not treated7

Outcome measures

PrimaryProgression-free Survival

Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.

Time frame:
Baseline to the end of the study (up to 2 years 10 months)
Reported as:
Median · Months
Progression-free Survival
MonthsBevacizumab + Paclitaxel + Gemcitabine
Progression-free Survival11.51 (9.01 to 17.59)
SecondaryPercentage of Participants With an Objective Response

An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum.

Time frame:
Baseline to the end of the study (up to 2 years 10 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Objective Response
Percentage of participantsBevacizumab + Paclitaxel + Gemcitabine
Percentage of Participants With an Objective Response72.37 (60.91 to 82.01)
SecondaryDuration of the Objective Response

Duration of the objective response is defined as the time from a complete or partial response to disease progression or death due to disease.

Time frame:
Baseline to the end of the study (up to 2 years 10 months)
Reported as:
Median · Months
Duration of the Objective Response
MonthsBevacizumab + Paclitaxel + Gemcitabine
Duration of the Objective Response12.39 (7.63 to 15.16)
SecondaryOverall Survival

Overall survival is defined as the time from the first dose of study medication until death.

Time frame:
Baseline to the end of the study (up to 2 years 10 months)
Reported as:
Median · Months
Overall Survival
MonthsBevacizumab + Paclitaxel + Gemcitabine
Overall Survival27.39 (21.86 to NA)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Paclitaxel + Gemcitabine—21/82 (25.6%)82/82 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventBevacizumab + Paclitaxel + Gemcitabine
FeverInfections and infestations4/82
Catheter site infectionInfections and infestations2/82
AnorexiaGastrointestinal disorders1/82
Gastrointestinal perforationGastrointestinal disorders1/82
VomitingGastrointestinal disorders1/82
DehydrationGastrointestinal disorders1/82
DiarrhoeaGastrointestinal disorders1/82
Febrile neutropeniaInfections and infestations1/82
InfectionInfections and infestations1/82
Cardiac ischemia/infarctionCardiac disorders1/82
Most frequent other events
Showing 10 of 117
Most frequent other events
EventBevacizumab + Paclitaxel + Gemcitabine
Neuropathy: sensoryNervous system disorders62/82
FatigueGeneral disorders54/82
Haemorrhage, pulmonary/upper respiratory noseVascular disorders30/82
Pain oral-gumsGeneral disorders28/82
Hair loss/alopecia (scalp or body)Skin and subcutaneous tissue disorders28/82
NauseaGastrointestinal disorders27/82
Neutrophils lowBlood and lymphatic system disorders26/82
VomitingGastrointestinal disorders25/82
DiarrhoeaGastrointestinal disorders20/82
Rash/desquamationSkin and subcutaneous tissue disorders20/82

Baseline characteristics

Intent-to-treat population: All participants enrolled in the study.

Age, Continuous
Age, Continuous(years)Bevacizumab + Paclitaxel + Gemcitabine
Mean52.20 ± 12.48
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Paclitaxel + Gemcitabine
Female89
Male1
08

Study locations

23 sites
  • Elda, Alicante 03600, Spain
  • Manresa, Barcelona 08243, Spain
  • Cádiz, Cadiz 11009, Spain
  • Las Palmas de Gran Canaria, Las Palmas 35016, Spain
  • Alcorcon, Madrid 28922, Spain
  • Marbella, Malaga 29600, Spain
  • Vigo, Pontevedra 36214, Spain
  • Sagunto, Valencia 46520, Spain
  • Barcelona, 08022, Spain
  • Barcelona, 08907, Spain
  • Burgos, 09006, Spain
  • Cordoba, 14004, Spain
  • Granada, 18003, Spain
  • Granada, 18014, Spain
  • Huelva, 21005, Spain
  • Jaen, 23007, Spain
  • Lugo, 27004, Spain
  • Madrid, 28041, Spain
  • Madrid, 28222, Spain
  • Murcia, 30008, Spain
  • Sevilla, 41009, Spain
  • Sevilla, 41014, Spain
  • Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Dec 2011 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2009
First posted
Feb 18, 2009
Start
Jan 2009
Primary completionActual
Dec 2011
CompletionActual
Jan 2013
Results first posted
Jun 26, 2014
Last update
Jul 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00846027
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 18, 2009
Start date
Jan 2009
Primary completion
Dec 2011
Completion
Jan 2013
Results posted
Jun 26, 2014
Last update
Jul 23, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Paclitaxel · Gemcitabine

Start the discussion